SCHEMBL91526

SCHEMBL91526

CN(C)C1(C)CNC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9146158 0.97
Hydrochloric Acid SCHEMBL30077928 0.97
SCHEMBL8942085 0.83
SCHEMBL24900660 0.77
SCHEMBL4287458 0.77
SCHEMBL31678523 0.75
Hydrochloric Acid SCHEMBL31209348 0.75 HTR2A (0.31)
Hydrochloric Acid SCHEMBL30632741 0.75 HTR2A (0.31)
Hydrochloric Acid SCHEMBL26685428 0.75 HTR2A (0.31)
SCHEMBL30069359 0.73 HTR2A (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12486260-B2 Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer MERCK PATENT GMBH (DE) 2025-12-02 US claimed
US-20220127254-A1 INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER MERCK PATENT GMBH (DE) 2022-04-28 US claimed
US-20250320213-A1 Nitrogen-Containing Heterocyclic Compounds PFIZER INC. (US) 2025-10-16 US disclosed
US-12441727-B2 Tricyclic compounds as inhibitors of KRAS INCYTE CORPORATION (US) 2025-10-14 US disclosed
US-20250304577-A1 TYK2 INHIBITORS BIOGEN MA INC. 2025-10-02 US disclosed
US-20250270220-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2025-08-28 US disclosed
US-12398135-B2 Dimethyl amino azetidine amides as JAK inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2025-08-26 US disclosed
US-20250188073-A1 TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS INCYTE CORP (US) 2025-06-12 US disclosed
WO-2025111582-A1 AZA-TETRACYCLIC OXAZEPINE INHIBITORS OF KRAS-G12D GENENTECH, INC. (US) 2025-05-30 WO disclosed
US-12304915-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2025-05-20 US disclosed
EP-4548918-A2 TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS Incyte Corporation (US) 2025-05-07 EP disclosed
US-20090306066-A1 PEPTIDE DEFORMYLASE INHIBITORS GLAXOSMITHKLINE LLC 2009-12-10 US disclosed
US-20090233901-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed
US-20070259869-A1 Aminopyrimidines useful as kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-11-08 US disclosed
US-20070179125-A1 Aminopyrimidines useful as kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2007-08-02 US disclosed
US-5556861-A 1,8 benzonaphthyridine derivatives and antimicrobial compositions LABORATOIRE ROGER BELLON (FR) 1996-09-17 US disclosed
EP-0388298-B1 Derivatives of pyridone carboxylic acids substituted by an azetidine, their preparation and their use as medicines ESTEVE LABOR DR (ES) 1995-06-21 EP disclosed
EP-0324298-B1 7-(1-AZETIDINYL)-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXYLIC-ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 1992-12-23 EP disclosed
EP-0388298-A2 Derivatives of pyridone carboxylic acids substituted by an azetidine, their preparation and their use as medicines LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 1990-09-19 EP disclosed
EP-0324298-A1 7-(1-Azetidinyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic-acid derivatives, their preparation and their use as medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 1989-07-19 EP disclosed